Effectiveness and safety of Jinshuibao capsules(金水宝胶囊)in treatment of residual cardiopulmonary symptoms in convalescent patients of coronavirus disease 2019:a pilot randomized,double-blind,placebo-controlled clinical trial

OBJECTIVE:To evaluate the effectiveness and safety of Jinshuibao capsules(金水宝胶囊),a Traditional Chinese Medicine(TCM),in the treatment of residual cardiopulmonary symptoms in convalescent corona virus disease 2019(COVID-19)patients.METHODS:A total of 200 participants with COVID-19 in convalescence phase were randomly assigned into two groups at a 1:1 ratio in this multicenter randomized,double-blind,placebo-controlled trial.One group received Jinshuibao capsules,and the other received placebo.The patients were followed up at one and two weeks of treatment.Five symptoms(dry cough,shortness of breath,sweating,chest tightness and palpitation)improvement rates and full recovery rates were compared.RESULTS:All baseline characteristics were comparable between the two groups.After two weeks of treatment,symptom improvement rates for dry cough(74.00%vs 50.00%,P=0.015),shortness of breath(78.95%vs 46.15%,P<0.001),sweating(80.00%vs 57.75%,P=0.004),chest tightness(87.06%vs 60.47%,P<0.001)and palpitation(82.50%vs 64.56%,P=0.010)were significantly higher in the Jinshuibao group compared with the control group.Meanwhile,Jinshuibao capsules treatment also displayed more satisfactory full recovery rates of all five symptoms(dry cough 58.00%vs 19.57%,shortness of breath 18.95%vs 7.69%,sweating 36.00%vs 19.72%,chest tightness 32.94%vs 13.95%,and palpitation 48.75%vs 29.11%)in participants with COVID-19 in convalescence phase compared with the control group(P<0.05).No severe adverse events were reported in either group.CONCLUSIONS:Jinshuibao capsules have the potential to improve residual cardiopulmonary symptoms in convalescent COVID-19 patients,with few adverse events.

Comparison on Efficacy between Astragalus-Polygonum Anti-Fibrosis Decoction and Jinshuibao (金水宝) Capsule in Treating Liver Fibrosis of Chronic Hepatitis B

Objective: To observe the efficacy of Astragalus Polygonum Anti Fibrosis decoction (APAFD)and Jinshuibao capsule (JSBC) in treating liver fibrosis of chronic hepatitis B. Methods: Ninety two cases of liver fibrosis of chronic hepatitis B were randomly divided into group A and group B. Patients in group A received APAFD for 48 weeks, and in group B, they received JSBC for 48 weeks. The effects on the level change of hyaluronic acid (HA), laminin (LN), pro collagen Ⅲ (PCⅢ) and collagen Ⅳ (CⅣ) as well as liver functional tests and liver biochemical parameters before and after treatment were observed.Results: Level of serum HA, LN, PCⅢ and CⅣ in group A declined more obviously than that of group B, the difference was significant ( P <0.01). The liver functional tests such as total bilirubin (TB), alanine aminotransferase (ALT), albumin/globulin (A/G) ratio, hepatitis related serum biochemical parameters such as cholylglycine (CG), serum ferritin (SF), prealbumin (PC) of group A were all improved more significantly than that of group B ( P <0.01).Conclusion: APAFD is more effective than JSBC in treating liver fibrosis of chronic hepatitis B and in the inhibition of hepatic inflammation, hence it is a good composite Chinese herbal preparation against liver fibrosis.

Effects of Feiwei granules in the treatment of idiopathic pulmonary fibrosis:a randomized and placebo-controlled trial

OBJECTIVE： To document the therapeutic effects of Feiwei granules （FGs） for idiopathic pulmonary fi-brosis （IPF）.METHODS： One hundred cases with IPF were ran- domized into the treatment group （80） and control group （20）. Both groups were given basic treat- ment with prednisone. The treatment group was given FGs, and the control group was given Jinshui- bao capsules （JCs）. Treatment lasted for 6 months. The Medical Research Council Dyspnea Scale （MRCDS）, the Saint George＇s Hospital Respiratory Questionnaire （SGHRQ）, pulmonary function, the Traditional Chinese Medicine Syndrome Score （TC- MSS）, 6-min walking test （6MWT） and blood gas analyses were recorded before the study as well as 3 months and 6 months after treatment.RESULTS： FGs showed greater efficacy than the control in certain parameters between before the study and 6 months, and between 3 months and 6 months, in the MRCDS, some indicators in the SGHRQ, and the TCMSS. There were no significant differences between the treatment group and con- trol group in the remainder of the indices evaluat- ed. In the treatment group, there were significant differences in before and after treatment in the MRCDS, SGHRQ, TCMSS and 6MWT.